Sunderdiek U, Korbmacher B, Gams E, Schipke J D
Department of Thoracic and Cardiovascular Surgery, Heinrich-Heine University, Moorenstrasse 5, 40225, Düsseldorf, Germany.
Eur J Cardiothorac Surg. 2000 Jul;18(1):83-9. doi: 10.1016/s1010-7940(00)00413-9.
In stunned myocardium oxygen consumption is relatively high compared with the reduced ventricular function. On the other hand, inotropic stimulation is frequently required to improve postischemic ventricular dysfunction. However, inotropic agents which act via intracellular increased calcium result in a higher oxygen demand. Therefore Ca(2+)-sensitization might be a favorable alternative.
The effects of a novel Ca(2+)-sensitizer (EMD 60263, 10 microM, group 1) were compared with a phosphodiesterase (PDE) III-inhibitor (enoximon, 20 microM, group 2) on 14 isolated, blood-perfused rabbit hearts during reperfusion after a global ischemia of 20 min. Ventricular function, the pressure-volume area (PVA, a measure of total mechanical work), and total myocardial oxygen consumption (MVO(2)) were assessed. Contractile efficiency (EF(cont)), derived from the reciprocal of the slope of the MVO(2)-PVA relation, and external efficiency (EF(ex), stroke work/MVO(2)), were calculated.
At matched heart rate (group 1: 141+/-10 min(-1) group 2: 151+/-28 min(-1)) and end-diastolic volume (1.3+/-0.2 ml) systolic variables were significantly decreased in stunned myocardium: LVP(max) to 57+/-13% of control value in group 1 and to 76+/-7% in group 2, aortic flow to 20+/-4 vs. 25+/-8%. PVA was decreased to 57+/-13 and 67+/-11%, MVO(2) was non-significantly decreased to 73+/-22 and 88+/-14%. After administration of either inotropic agent LVP(max) was significantly improved to 96+/-12 vs. 90+/-8% compared with preischemic levels, aortic flow to 103+/-24 vs. 88+/-9%, and PVA 99+/-11 vs. 89+/-16%, respectively. EMD 60263 increased MVO(2) to control levels (107+/-9%), and enoximon raised MVO(2) even more significantly above control (139+/-13%). Both myocardial efficiency indices were significantly diminished during reperfusion: EF(ex) to 14+/-9 vs. 23+/-7% and EF(cont) to 71+/-7 vs. 65+/-9% compared with preischemic levels. EF(ex) (109+/-21%) was significantly, but EF(cont) only slightly (84+/-11%) increased after administration of EMD 60263, whereas EF(ex) (57+/-13%) and EF(cont) (71+/-12%) remained depressed after enoximon.
In stunned myocardium, the decreased efficiency indices show that energy utilization is disturbed. Both agents recruited an inotropic reserve, whereas Ca(2+)-sensitization seemed to be more favorable in terms of myocardial efficiency indices. These results indicate that alteration of myocardial calcium sensitivity contributes a major part to postischemic dysfunction. Therefore, Ca(2+)-sensitization may potentially be a superior method for inotropic support in the postischemic heart.
在顿抑心肌中,与降低的心室功能相比,氧消耗相对较高。另一方面,常常需要应用正性肌力刺激来改善缺血后的心室功能障碍。然而,通过增加细胞内钙起作用的正性肌力药物会导致更高的氧需求。因此,钙增敏作用可能是一种更好的选择。
将一种新型钙增敏剂(EMD 60263,10微摩尔,第1组)与一种磷酸二酯酶(PDE)III抑制剂(依诺昔酮,20微摩尔,第2组)对14个离体、血液灌注的兔心脏在20分钟全心缺血后的再灌注过程中的作用进行比较。评估心室功能、压力-容积面积(PVA,总机械功的一种测量指标)和心肌总氧消耗(MVO₂)。计算收缩效率(EFcont,源自MVO₂-PVA关系斜率的倒数)和外在效率(EFex,每搏功/MVO₂)。
在匹配的心率(第1组:141±10次/分钟,第2组:151±28次/分钟)和舒张末期容积(1.3±0.2毫升)时,顿抑心肌的收缩期变量显著降低:第1组左心室最大压力(LVPmax)降至对照值的57±13%,第2组降至76±7%,主动脉血流降至20±4%对25±8%。PVA降至57±13%和67±11%,MVO₂无显著降低,分别降至73±22%和88±14%。给予任何一种正性肌力药物后,与缺血前水平相比,LVPmax显著改善至96±12%对90±8%,主动脉血流至103±24%对88±9%,PVA分别为99±11%对89±16%。EMD 60263将MVO₂提高至对照水平(107±9%),依诺昔酮使MVO₂比对照水平升高得更显著(139±13%)。在再灌注期间,两种心肌效率指标均显著降低:与缺血前水平相比,EFex降至14±9%对23±7%,EFcont降至71±7%对65±9%。给予EMD 60263后,EFex(109±21%)显著升高,但EFcont仅略有升高(84±11%),而给予依诺昔酮后,EFex(57±13%)和EFcont(71±12%)仍降低。
在顿抑心肌中,降低的效率指标表明能量利用受到干扰。两种药物都调动了正性肌力储备,而就心肌效率指标而言,钙增敏作用似乎更有利。这些结果表明,心肌钙敏感性的改变是缺血后功能障碍的主要原因。因此,钙增敏作用可能是缺血后心脏正性肌力支持的一种更优方法。